CD19 and lymphoma: In a recent phase 1 trial of a new CD19 CAR-T therapy, featuring a fully humanised scFv and a hinge and transmembrane domain derived from CD8α, the anti-lymphoma effect appeared to rival licensed CD19 CAR-T products, but ICANS was only observed in 1 out of 20 (5%) recipients [37].